Sugi Predict

Sugi Predict / Compounds / SCHEMBL2683392

SCHEMBL2683392

SCHEMBL2683392

CC(C)(C)OC(=O)N1C[C@H](O)C[C@@H]1CO

nearest known ligand 0.49

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.49
▸ CYP1A2 P05177 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ CHRM2 P08172 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ CHRM3 P20309 1/20 0.45
▸ SRC P12931 8/20 0.41
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HSD11B1 P28845 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11099691 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL1368985 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL5155598 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL12235723 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL15909556 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL12824048 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL584549 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL6421616 0.90 NR1H2 (0.48) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL1722772 0.87 CYP1A2 (0.45) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL20371652 0.87 CYP1A2 (0.45) NR1H2CYP1A2POLBCYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116891-A1 Oxazepin Derivative TEIJIN PHARMA LTD (JP) 2026-04-30 — — US disclosed
EP-4359402-B1 IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2026-03-11 — — EP disclosed
US-12384761-B2 Imidazolo indazole compounds as JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2025-08-12 — — US disclosed
EP-4512811-A1 OXAZEPINE DERIVATIVE Teijin Pharma Limited (JP) 2025-02-26 — — EP disclosed
EP-4359402-A1 IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS Theravance Biopharma R&D IP, LLC (US) 2024-05-01 — — EP disclosed
CN-117886814-A PD-1/PD-L1 small molecule inhibitor and application thereof in medicines 广东东阳光药业股份有限公司 2024-04-16 — — CN disclosed
CN-117813298-A Imidazole indazole compounds as JAK inhibitors 施万生物制药研发IP有限责任公司 2024-04-02 — — CN disclosed
US-20240092758-A1 IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC 2024-03-21 — — US disclosed
EP-3559007-B1 SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY DAIICHI SANKYO CO LTD (JP) 2023-08-16 — — EP disclosed
WO-2022272020-A1 IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2022-12-29 — — WO disclosed
US-20090324511-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-12-31 — — US disclosed
US-7625909-B2 Substituted quinazolinone compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-12-01 — — US disclosed
US-7625909-B2 Substituted quinazolinone compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-12-01 — — US disclosed
US-7625909-B2 Substituted quinazolinone compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-12-01 — — US disclosed
US-7368453-B2 Quinazolinone compounds with reduced bioaccumulation CHIRON CORPORATION (US) 2008-05-06 — — US disclosed
US-7368453-B2 Quinazolinone compounds with reduced bioaccumulation CHIRON CORPORATION (US) 2008-05-06 — — US disclosed
US-7368453-B2 Quinazolinone compounds with reduced bioaccumulation CHIRON CORPORATION (US) 2008-05-06 — — US disclosed
US-20070197533-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds ANADYS PHARMACEUTICALS, INC. (US) 2007-08-23 — — US disclosed
US-20050192297-A1 Quinazolinone compounds with reduced bioaccumulation CHIRON CORPORATION GLAXOSMITHKLINE 2005-09-01 — — US disclosed
US-5969135-A COMPOUNDS FOR USE AS ANTISENSE CONTROL OF GENE EXPRESSION AND HYBRIDIZATION ICN PHARMACEUTICALS, INC. (US) 1999-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324511-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 NR1H2 2912/4885CYP1A2 4662/4885POLB 3536/4885
US-20240092758-A1 IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS JAK1, JAK3, JAK2 NR1H2 2644/4885CYP1A2 489/4885POLB 4014/4885
US-12384761-B2 Imidazolo indazole compounds as JAK inhibitors JAK1, JAK3, JAK2 NR1H2 2644/4885CYP1A2 489/4885POLB 4014/4885
US-20070197533-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds DDC, DPP3, AMPD3 NR1H2 3695/4885CYP1A2 1210/4885POLB 760/4885
US-20050192297-A1 Quinazolinone compounds with reduced bioaccumulation MC4R, MC2R, MC3R NR1H2 781/4885CYP1A2 255/4885POLB 2626/4885
US-20260116891-A1 Oxazepin Derivative HCRTR2, HCRTR1, OXTR NR1H2 71/4885CYP1A2 899/4885POLB 4790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.